Navigation Links
BioReliance Launches Next-Generation Genotoxicity Screening Service
Date:9/12/2007

ROCKVILLE, Md., Sept. 12 /PRNewswire/ -- BioReliance Corporation, a leading contract services organization for the biopharmaceutical and pharmaceutical industries, has contracted with Gentronix to offer their GreenScreen HC in vitro assay as a major part of BioReliance's portfolio of genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic potential earlier in the preclinical development process, using only a few milligrams of test compound as opposed to the gram quantities required by current ICH regulatory tests.

John Nicholson, Chairman and CEO of Gentronix, comments, "We are delighted to complete this agreement with BioReliance, a company regarded as a global leader in genetic toxicology testing services." "This new high-throughput assay from Gentronix furthers BioReliance's ability to meet customer demand for faster and more effective genotoxic screening services," adds David Bruning, Senior Director, Toxicology Operations at BioReliance. "The GreenScreen HC and Ames II assays, when combined, offer highly predictive and sensitive detection of genotoxic compounds while minimizing false positives seen with other in vitro assays, accelerating the development process."

GreenScreen HC is a unique human cell-based genotoxicity screening assay that links the regulation of the human Growth Arrest and DNA Damage (GADD45a) gene to the production of Green Fluorescent Protein (GFP). Cells that have incurred DNA damage upon exposure to a test compound express higher levels of detectable GFP.

GreenScreen HC only requires 1 mg of starting material to demonstrate high specificity, in contrast to other in vitro genetic toxicology assays that often provide false positive results. GreenScreen HC is able to detect multiple mechanistic classes of genotoxic agents, including aneugens, and is easily adapted to automatic robotic platforms.

About Gentronix

Gentronix is an innovative biotechnology company helping to accelerate the pace of drug development in the pharmaceutical industry. Gentronix is developing a range of productivity-enhancing tools for scientists in the drug discovery field, designed to ease or remove current bottlenecks in preclinical research and development. Gentronix's first product release, GreenScreen, successfully combines expertise in molecular biology and analytical science to address the ADMET bottleneck in lead candidate selection, focusing specifically on genotoxicity screening. GreenScreen products are for use in genetic toxicity screening and can contribute to the selection of lead collections enriched with compounds lacking genotoxicity. For more information, visit http://www.gentronix.co.uk .

Contact

Peter McCulloch

Director, Business Development

peter.mcculloch@gentronix.co.uk

+44 161 606 7268

About BioReliance

BioReliance Corporation is a leading contract services organization, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing and lab animal health diagnostics for the biopharmaceutical and pharmaceutical industries. The Company provides cost-effective services to over 600 clients annually, including most of the largest pharmaceutical and biopharmaceutical companies in the world. BioReliance is headquartered in Rockville, Maryland and has additional facilities in Glasgow, Scotland and Stirling, Scotland. For more information, visit http://www.bioreliance.com .

Contact

David Bruning

Senior Director, Business Operations, Toxicology and LADS

david.bruning@bioreliance.com

+1 301.610.2653


'/>"/>
SOURCE BioReliance Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... and PETACH TIKVAH, ... -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a ... for neurodegenerative diseases, announced financial results for ... "2016 was a highly successful and ... achievements and significant progress made on clinical, ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... Bactana ... and hormones in the world’s food supply through enhancement of the gut microbiota, today ... round included Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and ...
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" ... , a new risk stratification test for breast cancer, via ... Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with ... risk for developing breast cancer.   ... BreastSentry measures the fasting plasma ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
Breaking Biology News(10 mins):